Rapid hemodilution is associated with increased sepsis and mortality among patients with severe acute pancreatitis.
BACKGROUND
Hemoconcentration may be an important factor that determines the progression of severe acute pancreatitis (SAP). In addition, it has been proposed that biomarkers may be useful in predicting subsequent necrosis in SAP. However, it is still uncertain whether hemodilution in a short term can improve outcome. We aimed to investigate the effect of rapid hemodilution on the outcome of patients with SAP.


METHODS
One hundred and fifteen patients were admitted prospectively according to the criteria within 24 hours of SAP onset. Patients were randomly assigned to either rapid hemodilution (hematocrit (HCT) < 35%, n = 56) or slow hemodilution (HCT > or = 35%, n = 59) within 48 hours of onset. Balthazar CT scores were calculated on admission, day 7, and day 14, after onset of the disease. Time interval for sepsis presented, incidence of sepsis within 28 days and in-hospital survival rate were determined.


RESULTS
The amount of fluid used in rapid hemodilution was significantly more than that used in slow hemodilution (P < 0.05) on the admission day, the first day, and the second day. There were significant differences between the rapid and slow hemodilution group in terms of hematocrit, oxygenation index, pH values, APACHE II scores and organ dysfunction at different time during the first week. There were significant differences in the time interval to sepsis in rapid hemodilution ((7.4 +/- 1.9) days) compared with the slow hemodilution group ((10.2 +/- 2.3) days), and the incidence of sepsis (78.6%) was higher in the rapid group compared to the slow (57.6%) in the first 28 days. The survival rate of the slow hemodilution group (84.7%) was better than the rapid hemodilution (66.1%. P < 0.05).


CONCLUSIONS
Rapid hemodilution can increase the incidence of sepsis within 28 days and in-hospital mortality. Hematocrit should be maintained between 30%-40% in the acute response stage.
Mao
En-Qiang
EQ
Department of Surgical Intensive Care Unit, Shanghai Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
Fei
Jian
J
Peng
Yi-Bing
YB
Huang
Jie
J
Tang
Yao-Qing
YQ
Zhang
Sheng-Dao
SD
D000208:Acute Disease / Q000401:mortality* / Q000628:therapy*; D000328:Adult; D005260:Female; D006438:Hemodilution / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000401:mortality* / Q000628:therapy*; D018805:Sepsis / Q000209:etiology* / Q000401:mortality*; D016896:Treatment Outcome